company background image
VNDA

Vanda Pharmaceuticals NasdaqGM:VNDA Stock Report

Last Price

US$10.80

Market Cap

US$611.2m

7D

3.0%

1Y

-33.5%

Updated

06 Dec, 2022

Data

Company Financials +
VNDA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends0/6

VNDA Stock Overview

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs.

Vanda Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vanda Pharmaceuticals
Historical stock prices
Current Share PriceUS$10.80
52 Week HighUS$18.00
52 Week LowUS$9.24
Beta0.52
1 Month Change2.56%
3 Month Change5.16%
1 Year Change-33.54%
3 Year Change-38.02%
5 Year Change-20.59%
Change since IPO11.57%

Recent News & Updates

Recent updates

Analysts Are More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

Feb 27
Analysts Are More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

An Intrinsic Calculation For Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Suggests It's 32% Undervalued

Nov 01
An Intrinsic Calculation For Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Suggests It's 32% Undervalued

Is There An Opportunity With Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) 47% Undervaluation?

Jun 28
Is There An Opportunity With Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) 47% Undervaluation?

It's Unlikely That The CEO Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Will See A Huge Pay Rise This Year

Jun 03
It's Unlikely That The CEO Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Will See A Huge Pay Rise This Year

This Insider Has Just Sold Shares In Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Mar 04
This Insider Has Just Sold Shares In Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Feb 12
Vanda Pharmaceuticals Inc. Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Are Insiders Selling Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock?

Dec 23
Are Insiders Selling Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock?

How Does Vanda Pharmaceuticals' (NASDAQ:VNDA) CEO Pay Compare With Company Performance?

Dec 02
How Does Vanda Pharmaceuticals' (NASDAQ:VNDA) CEO Pay Compare With Company Performance?

Shareholder Returns

VNDAUS BiotechsUS Market
7D3.0%1.9%-0.4%
1Y-33.5%-11.2%-20.6%

Return vs Industry: VNDA underperformed the US Biotechs industry which returned -6.5% over the past year.

Return vs Market: VNDA underperformed the US Market which returned -17.6% over the past year.

Price Volatility

Is VNDA's price volatile compared to industry and market?
VNDA volatility
VNDA Average Weekly Movement4.4%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: VNDA is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: VNDA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002278Mihael Polymeropouloshttps://www.vandapharma.com

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company’s marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness.

Vanda Pharmaceuticals Inc. Fundamentals Summary

How do Vanda Pharmaceuticals's earnings and revenue compare to its market cap?
VNDA fundamental statistics
Market CapUS$611.17m
Earnings (TTM)US$6.49m
Revenue (TTM)US$257.92m

94.2x

P/E Ratio

2.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VNDA income statement (TTM)
RevenueUS$257.92m
Cost of RevenueUS$24.28m
Gross ProfitUS$233.64m
Other ExpensesUS$227.15m
EarningsUS$6.49m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.11
Gross Margin90.59%
Net Profit Margin2.52%
Debt/Equity Ratio0%

How did VNDA perform over the long term?

See historical performance and comparison